Searchable abstracts of presentations at key conferences in endocrinology

ea0014p312 | (1) | ECE2007

VEGF, FGF and HGF in differentiated thyroid cancer

Przybylik-Mazurek Elwira , Huszno Bohdan

Pathogenesis of thyroid cancer involves a number of biological, and environmental factors. The growth factors have mitogenic, proliferative and dedifferentiating effects. Some of the cytokines: Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Hepatocyte Growth Factor (HGF) are detected in a neoplasmatic tissue. Moreover, there are affected thyroid cancer cell growth and function in vitro.Aim of the study: The aim of the s...

ea0014p152 | (1) | ECE2007

Evaluation of the efficacy of sandostatin LAR in the treatment of acromegaly

Baldys-Waligorska Agata , Krzentowska Anna , Golkowski Filip , Huszno Bohdan

Background: Somatostatin analogues are used to treat acromegaly patients who, following surgery, have not fulfilled cure criteria (hGH<2,5 ng/ml, IGF-1 below normal range for age and post-OGTT hGH <1,0 ng/ml). We evaluated the efficacy of Sandostatin LAR in managing such patients.Material and method: In our Clinic, 81 acromegaly patients (mean age 51.6±14.4 yrs) were registered over the years 1983-2005. Based on CT i MRI, macroadenoma and mi...

ea0014p544 | (1) | ECE2007

Topoisomerase II alpha expression in pituitary tumours – preliminary results

Trofimiuk Malgorzata , Adamek Dariusz , Czepko Ryszard , Sokolowski Grzegorz , Huszno Bohdan

Introduction: Topoisomerase II alpha is regarded as the important marker of cellular proliferation. Pituitary tumours are usually benign, but some of them are characterized by rapid growth, high recurrence rate and local invasiveness. Proliferation marker Ki-67 most commonly used in pituitary tumours is not entirely reliable as the indicator of the aggressive growth of the lesion. Topoisomerase II alpha expression assessment may be a valuable tool for identification such pitui...

ea0016oc2.8 | Thyroid | ECE2008

Graves’ ophthalmopathy in patients treated with radioiodine I-131

Baldys-Waligorska Agata , Buziak-Bereza Monika , Golkowski Filip , Kusnierz-Cabala Beata , Hubalewska-Dydejczyk Alicja , Huszno Bohdan

Introduction: Radioiodine treatment of hyperthyroidism of ophthalmopathy (GO) patients may cause or aggravate GO (in some 15%). We evaluated the activity and severity of ophthalmopathy in patients who acquired GO following radioiodine therapy.Materials and methods: Over the years 2003–2005, 1500 hyperthyroid patients were treated with radioiodine at our Clinic. Of these, 50.9% suffered from Graves’ disease. Following their radioiodine treatment...

ea0016p317 | Endocrine tumours | ECE2008

The prognostic factors in adrenocortical carcinoma

Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja , Kuzniarz Sylwia , Lubaszewska Katarzyna , Huszno Bohdan

Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Patients present signs of hormone excess: virilisation, Cushing’s syndrome or only enlarged abdominal mass. Incidentally ACC can be also detected in the ultrasonography. Some of ‘non-hypersecretory’ ACCs can produce non-bioactive hormones steroid precursors or not very big amount of them and sometimes patients present subclinical Cushing’s symptoms. Surgery and adjuvant radiotherapy and ...

ea0014p151 | (1) | ECE2007

Frequency of occurence of MEN1 syndrome in patients admitted with primary hyperthyroidism

Baldys-Waligorska Agata , Sokolowski Grzegorz , Trofimiuk Malgorzata , Golkowski Filip , Huszno Bohdan

Background: Primary hyperparathyroidism (HPT) is the most common endocrinopathy in MEN1 and usually its first clinical manifestation. Yet MEN1 is a rare disease, representing only 2–4% of all cases of HTP. We studied the frequency of MEN1 syndrome in HPT patients admitted to our Department.Methods: In a retrospective analysis of 84 suspected HPT patients hospitalized in 1999–2006, case reports of 11 patients with suspected MEN1 were analysed. M...

ea0014p543 | (1) | ECE2007

Meningiomas in patients diagnosed with acromegaly: the report of two cases

Trofimiuk Malgorzata , Adamek Dariusz , Czepko Ryszard , Sokolowski Grzegorz , Baldys-Waligorska Agata , Huszno Bohdan

Introduction: Only several cases of co-existing meningiomas and pituitary tumours secreting growth hormone (GH) have been described so far in patients not treated previously with irradiation.Aim: The aim of the study was to describe two cases of co-occurrence of acromegaly and meningioma and to discuss their relationship.Case reports: Case 1. 52-year old female complained of visual disturbances. She was diagnosed with pituitary mic...

ea0016p323 | Endocrine tumours | ECE2008

Neuroendocrine tumours (NETs): one centre experience

Hubalewska-Dydejczyk Alicja , Trofimiuk Malgorzata , Sowa-Staszczak Anna , Szybinski Piotr , Kulig Jan , Pach Dorota , Gilis-Januszewska Aleksandra , Huszno Bohdan

Background: NETs are rare tumours arising from dispersed neuroendocrine system. Nevertheless, their estimated prevalence increased lately, mostly due to progress in imaging, biochemical and histopathological diagnostics.The aim of the study was to present the characteristics of the NETs patient surveyed in our Endocrinology Department since 2000.Material and methods: One hundred and fifty-eight patients (males – 42.4%, females...

ea0014p107 | (1) | ECE2007

The role of radio-guided surgery (RGS) with the use of 99mTc-EDDA/HYNIC-octreotate in detection of unknown primary and secondary sites of neuroendocrine tumours of the gastrointestinal tract (GEP-NET) and improving the final outcome of patients

Hubalewska-Dydejczyk Alicja , Kulig Jan , Szybinski Piotr , Mikolajczak Renata , Sowa-Staszczak Anna , Fröss-Baron Katarzyna , Huszno Bohdan

Despite a wide spectrum of imaging diagnostics, GEP-NETs often stay undetectable until the time of dissemination. Removing of a primary tumour together with disseminated lymph nodes even with the presence of liver metastases is the most appropriate treatment to delay progression of the disease. SRS followed by RGS gives a possibility to detect occult GEP-NET intra-opratively. 99mTc-HYNIC/EDDA-octreotate, a somatostatin analogue with high affinity to sst2 was applied...

ea0014p172 | (1) | ECE2007

Diagnosis and treatment of the ACTH-secreting neuroendocrine pancreatic tumors

Aleksandra Gilis-Januszewska , Alicja Hubalewska-Dydejczyk , Malgorzata Trofimiuk , Dorota Pach , Magdalena Szurkowska , Monika Buziak-Bereza , Elwira Mazurek , Bohdan Huszno

Introduction: Neuroendocrine tumors secreting ACTH are a rare cause of Cushing’s syndrome.Diagnostic and therapeutical difficiulties might be caused due to different clinical picture of of neuroendocrine tumors.Patients, diagnostic and therapeutic approach: During 2004–2005 2 female patients 32-years old AL and 67-years old ZS were hospitalized in Endocrinology Department due to severe hypercorticism signs and symptoms. I...